These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 28438486

  • 1. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.
    Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH.
    Neurobiol Aging; 2017 Jul; 55():99-114. PubMed ID: 28438486
    [Abstract] [Full Text] [Related]

  • 2. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH.
    J Prev Alzheimers Dis; 2020 Jul; 7(4):256-264. PubMed ID: 32920628
    [Abstract] [Full Text] [Related]

  • 3. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
    Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH.
    J Neurosci; 2012 Jul 18; 32(29):9773-84. PubMed ID: 22815492
    [Abstract] [Full Text] [Related]

  • 4. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease.
    Burns LH, Wang HY.
    Neuroimmunol Neuroinflamm; 2017 Jul 18; 4(12):263-271. PubMed ID: 34295950
    [Abstract] [Full Text] [Related]

  • 5. Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer's Disease.
    Wang HY, Cecon E, Dam J, Pei Z, Jockers R, Burns LH.
    Int J Mol Sci; 2023 Sep 11; 24(18):. PubMed ID: 37762230
    [Abstract] [Full Text] [Related]

  • 6. Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.
    Wang HY, Trocmé-Thibierge C, Stucky A, Shah SM, Kvasic J, Khan A, Morain P, Guignot I, Bouguen E, Deschet K, Pueyo M, Mocaer E, Ousset PJ, Vellas B, Kiyasova V.
    Alzheimers Res Ther; 2017 Jul 27; 9(1):54. PubMed ID: 28750690
    [Abstract] [Full Text] [Related]

  • 7. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development.
    Burns LH, Pei Z, Wang HY.
    Drug Dev Res; 2023 Sep 27; 84(6):1085-1095. PubMed ID: 37291958
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
    Wu X, Kosaraju J, Zhou W, Tam KY.
    ACS Chem Neurosci; 2017 Mar 15; 8(3):676-685. PubMed ID: 28032988
    [Abstract] [Full Text] [Related]

  • 9. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.
    Hedberg MM, Clos MV, Ratia M, Gonzalez D, Lithner CU, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A.
    Neurodegener Dis; 2010 Mar 15; 7(6):379-88. PubMed ID: 20689242
    [Abstract] [Full Text] [Related]

  • 10. Genetic deletion of α7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer's disease-like pathology.
    Tropea MR, Li Puma DD, Melone M, Gulisano W, Arancio O, Grassi C, Conti F, Puzzo D.
    Prog Neurobiol; 2021 Nov 15; 206():102154. PubMed ID: 34453977
    [Abstract] [Full Text] [Related]

  • 11. Mitogen-activated protein kinase signaling pathways are involved in regulating α7 nicotinic acetylcholine receptor-mediated amyloid-β uptake in SH-SY5Y cells.
    Yang WN, Ma KG, Chen XL, Shi LL, Bu G, Hu XD, Han H, Liu Y, Qian YH.
    Neuroscience; 2014 Oct 10; 278():276-90. PubMed ID: 25168732
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
    Shin MK, Kim HG, Baek SH, Jung WR, Park DI, Park JS, Jo DG, Kim KL.
    Neurobiol Aging; 2014 May 10; 35(5):990-1001. PubMed ID: 24268884
    [Abstract] [Full Text] [Related]

  • 15. Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Yuksel M, Biberoglu K, Onder S, Akbulut KG, Tacal O.
    Biochimie; 2018 Mar 10; 146():105-112. PubMed ID: 29248542
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
    Isopi E, Granzotto A, Corona C, Bomba M, Ciavardelli D, Curcio M, Canzoniero LM, Navarra R, Lattanzio R, Piantelli M, Sensi SL.
    Neurobiol Dis; 2015 Sep 10; 81():214-24. PubMed ID: 25434488
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease.
    Oz M, Lorke DE, Yang KH, Petroianu G.
    Curr Alzheimer Res; 2013 Jul 10; 10(6):618-30. PubMed ID: 23627750
    [Abstract] [Full Text] [Related]

  • 20. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T, Ono K, Sakai A, Yamashita M, Mizuguchi M, Klein WL, Yamada M, Mori H, Tomiyama T.
    Brain; 2016 May 10; 139(Pt 5):1568-86. PubMed ID: 27020329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.